Developer docs
API playgroundTry for free, no card

Search company profiles

Pendulum Therapeutics

Full company profile

uuid0000at1

Namestring
Pendulum Therapeutics
Legal namestring
Pendulum Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Pendulum Therapeutics is a San Francisco-based biotechnology company founded in 2013 that develops and commercializes next-generation probiotics and prebiotics targeting specific gut microbiome deficiencies. Its core technology platform combines DNA sequencing, proprietary strain identification, and oxygen-free fermentation manufacturing to produce live anaerobic bacterial strains, most notably Akkermansia muciniphila, which Pendulum was the first company to bring live to the U.S. market. The product portfolio includes Metabolic Daily (a five-strain flagship), Akkermansia (gut barrier support), Glucose Control (a clinically validated medical probiotic shown to reduce A1C by 0.6 percentage points and post-meal glucose spikes by 32.5% in type 2 diabetes), Polyphenol Booster, and the newly launched Gut Fuel prebiotic fiber line; Glucose Control's clinical results were published in BMJ Open Diabetes Research & Care, and the company holds 18 granted patents with 66 pending applications.

Pendulum sells primarily through a direct-to-consumer subscription model on pendulumlife.com (SKUs priced $25-$99 per month, HSA/FSA eligible, with a 30% referral discount and a 90-day A1C trial on Glucose Control), supplemented by an affiliate program, a healthcare provider channel, and a wholesale program. In April 2026, Pendulum expanded into physical retail with a nationwide launch at Sprouts Farmers Market across the probiotics aisle and Forager Finds displays. The company targets health-conscious consumers, type 2 diabetes patients, gut-health seekers, GLP-1 medication users, and women's health segments, with growing clinical validation from partnerships with Mayo Clinic (first investor and research partner since 2013), Mass General, Ohio State Wexner Medical Center, Australian Catholic University, Texas Christian University, and the University of São Paulo. Pendulum has raised over $120 million across multiple funding rounds from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures, Mayo Clinic, and Fonterra, with celebrity investor Halle Berry serving as Chief Communications Officer and Madison Reed founder Amy Errett joining the Board in 2026 to support mainstream consumer expansion.

Short descriptiontext

Pendulum Therapeutics is a San Francisco-based microbiome biotechnology company founded in 2013 that develops and sells clinically validated probiotic and prebiotic supplements, including the first live Akkermansia muciniphila product in the U.S. and Glucose Control for type 2 diabetes, primarily through a DTC subscription model now expanding into Sprouts Farmers Market retail.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome probiotics, gut health supplements, diabetes probiotics, prebiotic fiber supplements, microbiome therapeutics
Industry2 codes
PRIMARYCRADAGAF
Probiotics & Digestive Health Supplements
SECONDARYAFAJAKAE
Probiotics (Strains, Spore-Formers, Synbiotic Components)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Biological Product (except Diagnostic) Manufacturing325414
  • Food (Health) Supplement Retailers456191
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Medicinal Chemicals & Botanical Products2833
Product category
Microbiome Probiotic Supplements
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Direct-to-Consumer Probiotic Product Sales
TypeSubscription Recurring
Description

Primary revenue stream through pendulumlife.com e-commerce platform. Products sold as one-time purchases or subscription memberships with 30% referral discount and up to 40% savings with HSA/FSA eligibility. Subscription model provides recurring revenue with customer loyalty incentives.

pendulumlife.com
2Retail Distribution
TypeOne Time License
Description

Products sold through Sprouts Farmers Market nationwide as of April 2026, with placement in probiotics aisle and Forager Finds displays. Wholesale program available for additional retail partnerships.

prnewswire.com
3Affiliate Program
TypeAffiliate Referral
Description

30-day cookie duration affiliate program offering up to 20% commission for promoters. Third-party tracking through Impact platform.

pendulumlife.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Infrastructure
Pricing details7 tiers
1Metabolic Daily 4-in-1 probiotic for gut and metabolism
ModelSubscriptionBilling cadenceMonthly
Notes

$49/month with subscription (starts at); $69 one-time purchase. 30-day money-back guarantee.

2Akkermansia gut health probiotic
ModelSubscriptionBilling cadenceMonthly
Notes

$54/month with subscription (starts at). 30-day money-back guarantee.

3Glucose Control for A1C reduction
ModelSubscriptionBilling cadenceMonthly
Notes

$99/month with subscription (starts at). 90-day trial period required for money-back guarantee.

4Polyphenol Booster antioxidant supplement
ModelSubscriptionBilling cadenceMonthly
Notes

$25/month with subscription (starts at). 30-day money-back guarantee.

5Gut Fuel prebiotic fiber powder pouch
ModelUnit PricingBilling cadenceMonthly
Notes

$32 with subscription (starts at); $40 one-time. 30-serving pouches.

6Gut Fuel on-the-go packets
ModelUnit PricingBilling cadenceMonthly
Notes

$22 with subscription (starts at). 15-count individual serving sticks.

7Bundle and Save options
ModelSubscriptionBilling cadenceMonthly
Notes

Metabolic Daily Bundle (Metabolic Daily + Polyphenol Booster) at $74/month vs $84 separate. 3-month bundles recommended for full gut adaptation results.

pendulumlife.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pendulum Therapeutics develops and sells next-generation probiotic and prebiotic supplements built on proprietary bacterial strains, most notably live Akkermansia muciniphila and a clinically validated five-strain formulation. Products are manufactured in the company's own oxygen-free U.S. facility and target consumer and clinical use cases including gut barrier integrity, metabolic health, and A1C reduction in type 2 diabetes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Reduces A1C by 0.6 percentage points in type 2 diabetes patients on metformin
+6 more records
Product overview1 text field

Pendulum Therapeutics offers a portfolio of next-generation probiotic and prebiotic supplements centered on microbiome-targeted health solutions. The core product line consists of proprietary probiotic formulations featuring Akkermansia muciniphila and other anaerobic bacterial strains, including Metabolic Daily (4-in-1 daily probiotic), Akkermansia (targeted gut lining support), and Glucose Control (medical probiotic for type 2 diabetes management). These are complemented by the Polyphenol Booster add-on, which provides antioxidant support to enhance probiotic efficacy. The prebiotic Gut Fuel line (available in pouch and on-the-go packet formats) rounds out the portfolio as a fiber and polyphenol blend designed to nourish beneficial gut bacteria and support metabolic health. All products are manufactured in the company's own oxygen-free facility in the U.S. and are backed by clinical research conducted in partnership with institutions like Mayo Clinic.

Product and service7 records
1Metabolic Daily
CategoryDaily Probiotic Supplement
Description

A 4-in-1 daily probiotic featuring five proprietary bacterial strains (Akkermansia muciniphila, Clostridium butyricum, Anaerobutyricum hallii, Clostridium beijerinckii, and Bifidobacterium infantis) designed to improve gut health, metabolism, mood, and energy levels. Contains live Akkermansia and is positioned as the flagship bestseller for adult consumers.

2Akkermansia
CategoryTargeted Probiotic Supplement
Description

A targeted probiotic supplement featuring Akkermansia muciniphila, a keystone bacterial strain that fortifies the gut lining, reduces gut permeability, and supports metabolic function. Marketed to consumers seeking gut barrier and leaky gut support.

3Glucose Control
CategoryMedical Probiotic for Type 2 Diabetes
Description

A five-strain medical probiotic formulation containing Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Eubacterium hallii, and Bifidobacterium infantis, plus a prebiotic. Produces butyrate to stimulate GLP-1 hormone release, providing nutritional management of type 2 diabetes with clinically demonstrated A1C reduction.

4Polyphenol Booster
CategoryAntioxidant Supplement
Description

An antioxidant-rich supplement containing grape seed extract and other plant-derived polyphenols designed to amplify probiotic performance by providing fuel for Akkermansia and other beneficial gut bacteria. Supports gut diversity and antioxidant protection.

5Gut Fuel Pouch
CategoryPrebiotic Fiber Supplement
Description

A mix-in prebiotic fiber and polyphenol supplement that delivers 6 grams of fiber per serving through a blend of resistant potato starch, baobab, acacia, oat beta-glucan, and grape seed extract. Designed to nourish beneficial gut bacteria and support GLP-1 signaling for metabolic health.

6Gut Fuel Packets
CategoryPrebiotic Fiber Supplement
Description

On-the-go individual serving packets of the Gut Fuel prebiotic fiber and polyphenol supplement, providing the same 6g fiber blend as the pouch format in convenient single-serve packaging.

7Metabolic Daily Bundle
CategoryProduct Bundle
Description

A bundled offering combining the Metabolic Daily flagship probiotic with the Polyphenol Booster at a discounted price ($74/month subscription vs $84 separate), enabling consumers to purchase the core probiotic along with its recommended complementary supplement.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-01-01
Description

Mayo Clinic is Pendulum's first investor and continuing research partner. The company is the first consumer microbiome company to co-develop a registry with Mayo Clinic. Partnership dating back to 2013 includes ongoing clinical research collaborations, with expanded scope into women's health and dermatology. Dr. Jay Pasricha serves as Chief of Medicine at Mayo Clinic on Pendulum's Medical Advisory Board. Dr. Purna Kashyap, MBBS, also from Mayo Clinic on Medical Advisory Board.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Nationwide retail distribution partnership launched April 2026, coinciding with Sprouts Wellness Week (April 22-28). Products available in probiotics aisle and featured on Forager Finds displays.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

PRO-PLATINUM clinical trial: Randomized, double-blind, placebo-controlled study investigating efficacy of probiotic intervention on gut and vaginal microbiome of ovarian cancer patients undergoing platinum chemotherapy. 124 participants, conducted by The Ohio State University Wexner Medical Center.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Phase 1 clinical trial on Fecal Microbiota Transplantation (FMT) for Auto-Brewery Syndrome, funded by NIH. Explores safety and tolerability of antibiotic pretreatment, microbial restoration via FMT, and daily administration of Pendulum Metabolic Daily for 9 months.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

OsteoPreP Study: Evaluating how Pendulum probiotics can support bone health in early postmenopausal women. 12-month double-blind, randomized, placebo-controlled trial with 160 participants. Professor Mattias Lorentzon from Mary MacKillop Institute for Health Research leading.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Triple-blinded, randomized, controlled clinical trial on next-generation synbiotic for individuals who are overweight or with obesity. Evaluating impacts of Pendulum Glucose Control on body composition, metabolic health, mood, and food behavior.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Randomized, double-blind, placebo-controlled trial evaluating antidepressant efficacy of adjunctive probiotic administration in participants with bipolar depression. 84 participants, 12-week study.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Groundbreaking research collaboration announced December 2024 to evaluate impact of novel next-generation probiotics on metabolic health.

9Halle Berry
Strategic tierCoreTypeGTM or Marketing Partner
Description

Oscar-winning actress Halle Berry invested in Pendulum and serves as Chief Communications Officer and brand evangelist since February 2023. Brings celebrity endorsement and wellness credibility to the brand.

bizjournals.com
10Amy Errett
Strategic tierMinorTypeOthers
Description

Madison Reed Founder and CEO appointed to Board of Directors in June 2026. Brings expertise in building consumer brands and scaling mission-driven businesses to guide Pendulum's expansion into mainstream consumer health.

prnewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct-to-consumer supplement brand with science-backed positioning, transparent ingredient sourcing, and a strong DTC subscription business. Comparable in target consumer demographic, premium DTC positioning, and clinical evidence-based marketing.

TypeDirect peer
Description

Direct-to-consumer microbiome company selling proprietary probiotic formulations (Seed Daily Synbiotic) with a strong scientific and clinical positioning. Highly comparable to Pendulum in target consumer, premium subscription model, and science-led marketing approach.

TypeDirect peer
Description

Personalized nutrition company combining gut microbiome testing with dietary recommendations and supplement products. Direct competitor for consumer mindshare around microbiome-driven health, with a similar science-backed subscription model and clinical research emphasis.

TypeDirect peer
Description

Microbiome testing and personalized nutrition/supplement company that analyzes gut microbiome samples to recommend customized prebiotic and probiotic formulations. Comparable target customer, DTC subscription model, and gut health focus.

TypeDirect peer
Description

Premium supplement brand offering practitioner-grade and DTC nutritional products with strong scientific validation and NSF/USP certifications. Comparable in science-led marketing, premium positioning, and clinical credibility, though broader portfolio than Pendulum.

6AG1 (Athletic Greens)
TypeDirect peer
Description

High-growth DTC nutrition company selling a comprehensive daily greens and probiotic powder with celebrity endorsements and a premium subscription model. Comparable in DTC scale, celebrity-driven marketing, and health-conscious consumer targeting.

TypeBroad incumbent
Description

Global food and dairy giant with a major probiotics portfolio (Actimel, Activia) and the Nutricia medical nutrition division. Operates across probiotics, functional nutrition, and microbiome research, competing indirectly for the same consumer health positioning.

8BioGaia
TypeDirect peer
Description

Swedish probiotics company with patented Lactobacillus reuteri strains used in supplements and infant formula. Direct competitor in the probiotics space with proprietary strain IP, though operates through healthcare professional and consumer health channels rather than primarily DTC.

TypeBroad incumbent
Description

Global bioscience company and one of the world's largest producers of probiotic bacterial cultures, supplying ingredients to supplement and dairy companies. Overlaps with Pendulum's strain-level microbiome science, but operates as a B2B ingredient supplier rather than a consumer brand.

TypeBroad incumbent
Description

Japanese multinational and global leader in probiotic functional beverages, with decades of Lactobacillus casei strain research. Competes for consumer share-of-stomach around gut health benefits, though in the functional beverage rather than supplement format.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pendulum Therapeutics

Microbiome Probiotic Supplementspendulumlife.com

Pendulum Therapeutics is a San Francisco-based microbiome biotechnology company founded in 2013 that develops and sells clinically validated probiotic and prebiotic supplements, including the first live Akkermansia muciniphila product in the U.S. and Glucose Control for type 2 diabetes, primarily through a DTC subscription model now expanding into Sprouts Farmers Market retail.

What Pendulum Therapeutics does

Pendulum Therapeutics is a San Francisco-based biotechnology company founded in 2013 that develops and commercializes next-generation probiotics and prebiotics targeting specific gut microbiome deficiencies. Its core technology platform combines DNA sequencing, proprietary strain identification, and oxygen-free fermentation manufacturing to produce live anaerobic bacterial strains, most notably Akkermansia muciniphila, which Pendulum was the first company to bring live to the U.S. market. The product portfolio includes Metabolic Daily (a five-strain flagship), Akkermansia (gut barrier support), Glucose Control (a clinically validated medical probiotic shown to reduce A1C by 0.6 percentage points and post-meal glucose spikes by 32.5% in type 2 diabetes), Polyphenol Booster, and the newly launched Gut Fuel prebiotic fiber line; Glucose Control's clinical results were published in BMJ Open Diabetes Research & Care, and the company holds 18 granted patents with 66 pending applications.

Pendulum sells primarily through a direct-to-consumer subscription model on pendulumlife.com (SKUs priced $25-$99 per month, HSA/FSA eligible, with a 30% referral discount and a 90-day A1C trial on Glucose Control), supplemented by an affiliate program, a healthcare provider channel, and a wholesale program. In April 2026, Pendulum expanded into physical retail with a nationwide launch at Sprouts Farmers Market across the probiotics aisle and Forager Finds displays. The company targets health-conscious consumers, type 2 diabetes patients, gut-health seekers, GLP-1 medication users, and women's health segments, with growing clinical validation from partnerships with Mayo Clinic (first investor and research partner since 2013), Mass General, Ohio State Wexner Medical Center, Australian Catholic University, Texas Christian University, and the University of São Paulo. Pendulum has raised over $120 million across multiple funding rounds from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures, Mayo Clinic, and Fonterra, with celebrity investor Halle Berry serving as Chief Communications Officer and Madison Reed founder Amy Errett joining the Board in 2026 to support mainstream consumer expansion.

Pendulum Therapeutics firmographics

Firmographics
Name
Pendulum Therapeutics
Legal name
Pendulum Therapeutics, Inc.
Website
https://pendulumlife.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
Pendulum Therapeutics is a San Francisco-based microbiome biotechnology company founded in 2013 that develops and sells clinically validated probiotic and prebiotic supplements, including the first live Akkermansia muciniphila product in the U.S. and Glucose Control for type 2 diabetes, primarily through a DTC subscription model now expanding into Sprouts Farmers Market retail.
Ownership category
akta.pro rank

Pendulum Therapeutics industry classification

Industry
Product category
Microbiome Probiotic Supplements
NAICS
Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Food (Health) Supplement Retailers (456191)
SIC
Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYCRADAGAF
Probiotics & Digestive Health Supplements
SECONDARYAFAJAKAE
Probiotics (Strains, Spore-Formers, Synbiotic Components)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

Keywords

  • Microbiome probiotics
  • Gut health supplements
  • Diabetes probiotics
  • Prebiotic fiber supplements
  • Microbiome therapeutics

Where Pendulum Therapeutics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Pendulum Therapeutics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Infrastructure

Revenue model

  1. Direct-to-Consumer Probiotic Product Sales: Primary revenue stream through pendulumlife.com e-commerce platform. Products sold as one-time purchases or subscription memberships with 30% referral discount and up to 40% savings with HSA/FSA eligibility. Subscription model provides recurring revenue with customer loyalty incentives.
  2. Retail Distribution: Products sold through Sprouts Farmers Market nationwide as of April 2026, with placement in probiotics aisle and Forager Finds displays. Wholesale program available for additional retail partnerships.
  3. Affiliate Program: 30-day cookie duration affiliate program offering up to 20% commission for promoters. Third-party tracking through Impact platform.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyMetabolic Daily 4-in-1 probiotic for gut and metabolism
SubscriptionMonthlyAkkermansia gut health probiotic
SubscriptionMonthlyGlucose Control for A1C reduction
SubscriptionMonthlyPolyphenol Booster antioxidant supplement
Unit PricingMonthlyGut Fuel prebiotic fiber powder pouch
Unit PricingMonthlyGut Fuel on-the-go packets
SubscriptionMonthlyBundle and Save options

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Pendulum Therapeutics product offering

Product offering

Core offering

Pendulum Therapeutics develops and sells next-generation probiotic and prebiotic supplements built on proprietary bacterial strains, most notably live Akkermansia muciniphila and a clinically validated five-strain formulation. Products are manufactured in the company's own oxygen-free U.S. facility and target consumer and clinical use cases including gut barrier integrity, metabolic health, and A1C reduction in type 2 diabetes.

Product overview

Pendulum Therapeutics offers a portfolio of next-generation probiotic and prebiotic supplements centered on microbiome-targeted health solutions. The core product line consists of proprietary probiotic formulations featuring Akkermansia muciniphila and other anaerobic bacterial strains, including Metabolic Daily (4-in-1 daily probiotic), Akkermansia (targeted gut lining support), and Glucose Control (medical probiotic for type 2 diabetes management). These are complemented by the Polyphenol Booster add-on, which provides antioxidant support to enhance probiotic efficacy. The prebiotic Gut Fuel line (available in pouch and on-the-go packet formats) rounds out the portfolio as a fiber and polyphenol blend designed to nourish beneficial gut bacteria and support metabolic health. All products are manufactured in the company's own oxygen-free facility in the U.S. and are backed by clinical research conducted in partnership with institutions like Mayo Clinic.

Differentiator

Problem solved

Functional benefit

Products and services

  • Metabolic Daily A 4-in-1 daily probiotic featuring five proprietary bacterial strains (Akkermansia muciniphila, Clostridium butyricum, Anaerobutyricum hallii, Clostridium beijerinckii, and Bifidobacterium infantis) designed to improve gut health, metabolism, mood, and energy levels. Contains live Akkermansia and is positioned as the flagship bestseller for adult consumers.
  • Akkermansia A targeted probiotic supplement featuring Akkermansia muciniphila, a keystone bacterial strain that fortifies the gut lining, reduces gut permeability, and supports metabolic function. Marketed to consumers seeking gut barrier and leaky gut support.
  • Glucose Control A five-strain medical probiotic formulation containing Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Eubacterium hallii, and Bifidobacterium infantis, plus a prebiotic. Produces butyrate to stimulate GLP-1 hormone release, providing nutritional management of type 2 diabetes with clinically demonstrated A1C reduction.
  • Polyphenol Booster An antioxidant-rich supplement containing grape seed extract and other plant-derived polyphenols designed to amplify probiotic performance by providing fuel for Akkermansia and other beneficial gut bacteria. Supports gut diversity and antioxidant protection.
  • Gut Fuel Pouch A mix-in prebiotic fiber and polyphenol supplement that delivers 6 grams of fiber per serving through a blend of resistant potato starch, baobab, acacia, oat beta-glucan, and grape seed extract. Designed to nourish beneficial gut bacteria and support GLP-1 signaling for metabolic health.
  • Gut Fuel Packets On-the-go individual serving packets of the Gut Fuel prebiotic fiber and polyphenol supplement, providing the same 6g fiber blend as the pouch format in convenient single-serve packaging.
  • Metabolic Daily Bundle A bundled offering combining the Metabolic Daily flagship probiotic with the Polyphenol Booster at a discounted price ($74/month subscription vs $84 separate), enabling consumers to purchase the core probiotic along with its recommended complementary supplement.

Quantifiable outcome

  • Reduces A1C by 0.6 percentage points in type 2 diabetes patients on metformin
  • +6 more outcomes

Companies that use Pendulum Therapeutics

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles5 records

Pendulum Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Pendulum Therapeutics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Mayo CliniccoreStrategic or Co-development Partner · 1 January 2013Mayo Clinic is Pendulum's first investor and continuing research partner. The company is the first consumer microbiome company to co-develop a registry with Mayo Clinic. Partnership dating back to 2013 includes ongoing clinical research collaborations, with expanded scope into women's health and dermatology. Dr. Jay Pasricha serves as Chief of Medicine at Mayo Clinic on Pendulum's Medical Advisory Board. Dr. Purna Kashyap, MBBS, also from Mayo Clinic on Medical Advisory Board.
  • Sprouts Farmers MarketcoreChannel Partner/ Reseller/ DistributorNationwide retail distribution partnership launched April 2026, coinciding with Sprouts Wellness Week (April 22-28). Products available in probiotics aisle and featured on Forager Finds displays.
  • The Ohio State University Wexner Medical CentercoreStrategic or Co-development PartnerPRO-PLATINUM clinical trial: Randomized, double-blind, placebo-controlled study investigating efficacy of probiotic intervention on gut and vaginal microbiome of ovarian cancer patients undergoing platinum chemotherapy. 124 participants, conducted by The Ohio State University Wexner Medical Center.
  • Massachusetts General HospitalcoreStrategic or Co-development PartnerPhase 1 clinical trial on Fecal Microbiota Transplantation (FMT) for Auto-Brewery Syndrome, funded by NIH. Explores safety and tolerability of antibiotic pretreatment, microbial restoration via FMT, and daily administration of Pendulum Metabolic Daily for 9 months.
  • Australian Catholic UniversitycoreStrategic or Co-development PartnerOsteoPreP Study: Evaluating how Pendulum probiotics can support bone health in early postmenopausal women. 12-month double-blind, randomized, placebo-controlled trial with 160 participants. Professor Mattias Lorentzon from Mary MacKillop Institute for Health Research leading.
  • Texas Christian UniversityminorStrategic or Co-development PartnerTriple-blinded, randomized, controlled clinical trial on next-generation synbiotic for individuals who are overweight or with obesity. Evaluating impacts of Pendulum Glucose Control on body composition, metabolic health, mood, and food behavior.
  • University of São Paulo (FMSUP)minorStrategic or Co-development PartnerRandomized, double-blind, placebo-controlled trial evaluating antidepressant efficacy of adjunctive probiotic administration in participants with bipolar depression. 84 participants, 12-week study.
  • GluCare.HealthminorStrategic or Co-development PartnerGroundbreaking research collaboration announced December 2024 to evaluate impact of novel next-generation probiotics on metabolic health.
  • Halle BerrycoreGTM or Marketing PartnerOscar-winning actress Halle Berry invested in Pendulum and serves as Chief Communications Officer and brand evangelist since February 2023. Brings celebrity endorsement and wellness credibility to the brand.
  • Amy ErrettminorOthersMadison Reed Founder and CEO appointed to Board of Directors in June 2026. Brings expertise in building consumer brands and scaling mission-driven businesses to guide Pendulum's expansion into mainstream consumer health.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Pendulum Therapeutics competitors and assessment

Company assessment

Direct peers

  • Ritual: Direct-to-consumer supplement brand with science-backed positioning, transparent ingredient sourcing, and a strong DTC subscription business. Comparable in target consumer demographic, premium DTC positioning, and clinical evidence-based marketing.
  • Seed Health: Direct-to-consumer microbiome company selling proprietary probiotic formulations (Seed Daily Synbiotic) with a strong scientific and clinical positioning. Highly comparable to Pendulum in target consumer, premium subscription model, and science-led marketing approach.
  • ZOE: Personalized nutrition company combining gut microbiome testing with dietary recommendations and supplement products. Direct competitor for consumer mindshare around microbiome-driven health, with a similar science-backed subscription model and clinical research emphasis.
  • Viome: Microbiome testing and personalized nutrition/supplement company that analyzes gut microbiome samples to recommend customized prebiotic and probiotic formulations. Comparable target customer, DTC subscription model, and gut health focus.
  • Thorne: Premium supplement brand offering practitioner-grade and DTC nutritional products with strong scientific validation and NSF/USP certifications. Comparable in science-led marketing, premium positioning, and clinical credibility, though broader portfolio than Pendulum.
  • AG1 (Athletic Greens): High-growth DTC nutrition company selling a comprehensive daily greens and probiotic powder with celebrity endorsements and a premium subscription model. Comparable in DTC scale, celebrity-driven marketing, and health-conscious consumer targeting.
  • BioGaia: Swedish probiotics company with patented Lactobacillus reuteri strains used in supplements and infant formula. Direct competitor in the probiotics space with proprietary strain IP, though operates through healthcare professional and consumer health channels rather than primarily DTC.

Broad incumbents

  • Danone (Nutricia): Global food and dairy giant with a major probiotics portfolio (Actimel, Activia) and the Nutricia medical nutrition division. Operates across probiotics, functional nutrition, and microbiome research, competing indirectly for the same consumer health positioning.
  • Novonesis (formerly Chr. Hansen): Global bioscience company and one of the world's largest producers of probiotic bacterial cultures, supplying ingredients to supplement and dairy companies. Overlaps with Pendulum's strain-level microbiome science, but operates as a B2B ingredient supplier rather than a consumer brand.
  • Yakult: Japanese multinational and global leader in probiotic functional beverages, with decades of Lactobacillus casei strain research. Competes for consumer share-of-stomach around gut health benefits, though in the functional beverage rather than supplement format.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Pendulum Therapeutics social profiles

Digital presence

Pendulum Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pendulum Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Pendulum Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pendulum Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pendulum Therapeutics

What does Pendulum Therapeutics do?

Pendulum Therapeutics develops and sells next-generation probiotic and prebiotic supplements built on proprietary bacterial strains, most notably live Akkermansia muciniphila and a clinically validated five-strain formulation. Products are manufactured in the company's own oxygen-free U.S. facility and target consumer and clinical use cases including gut barrier integrity, metabolic health, and A1C reduction in type 2 diabetes.

Is Pendulum Therapeutics a public or private company?

Pendulum Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pendulum Therapeutics founded?

Pendulum Therapeutics was founded in 2013. It employs 101 to 250 people.

Where is Pendulum Therapeutics based?

Pendulum Therapeutics is headquartered in San Francisco, United States, in the North America region.

How does Pendulum Therapeutics make money?

Three revenue lines are on record. Direct-to-Consumer Probiotic Product Sales are the primary driver. The others are retail Distribution and affiliate Program.

Who are Pendulum Therapeutics's main competitors?

Direct peers on record are Ritual, Seed Health, ZOE, Viome, Thorne, AG1 (Athletic Greens) and BioGaia. Broad incumbents are Danone (Nutricia), Novonesis (formerly Chr. Hansen) and Yakult.

Does Pendulum Therapeutics have an API?

No public API is recorded for Pendulum Therapeutics.

What industry is Pendulum Therapeutics in?

Pendulum Therapeutics's product category is Microbiome Probiotic Supplements. Its primary akta.pro industry code is CRADAGAF, Probiotics & Digestive Health Supplements, with a secondary code of AFAJAKAE, Probiotics (Strains, Spore-Formers, Synbiotic Components). Its NAICS code is 325411 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AktienEuropean court grants preliminary injunction against Pendulum and iHerb based on Caelus patentThe Unified Patent Court provisionally ordered Pendulum and iHerb to stop selling products containing a specific gut bacterium in several European countries. The injunction is based on Caelus's patent EP 2 753 187, which covers the bacterium's use. Caelus will proceed to full proceedings on the merits.PR NewswireEuropean court grants preliminary injunction against Pendulum and iHerb based on Caelus patentThe Unified Patent Court provisionally ordered Pendulum and iHerb to stop selling products containing a specific gut bacterium in eight European countries. The order is based on Caelus's patent EP 2 753 187, which covers the bacterium's use. Caelus will proceed to full proceedings on the merits.ForbesHow To Raise Capital When Your Biotech Has A Consumer BusinessAbdelahhad Barbour advises biotech founders to align consumer and scientific assets around a shared technology, as seen in Seed Health and Pendulum. He warns that consumer revenue alone does not reduce capital dependence if unit economics fail, citing 23andMe's decline. Financing should target inflection points, not just dilution.PR NewswireNutraceutical Ingredients Market worth $161.53 billion by 2031- Exclusive Report by MarketsandMarkets™The global nutraceutical ingredients market is projected to grow from $108.33 billion in 2026 to $161.53 billion by 2031, a CAGR of 7.3%. Asia Pacific is expected to be the largest and fastest-growing region, with human nutrition and functional proteins holding the largest shares.Nutritional OutlookPendulum Therapeutics launches first probiotic classified as a medical food to manage diabetesPendulum Therapeutics launched Pendulum Glucose Control, a medical probiotic for type 2 diabetes, claiming it lowers A1C and blood sugar spikes. The product is non-GMO, vegan, and gluten-free, and can be taken with metformin under physician supervision.Sequoia CapitalColleen Cutcliffe of Pendulum Therapeutics: Trusting Her GutColleen Cutcliffe, CEO of Pendulum Therapeutics, founded the biotech after her daughter's NICU stay, which she linked to microbiome issues. Pendulum's probiotic capsule helps lower glucose in type 2 diabetes, with a customer who lost 80 pounds. Cutcliffe aims to expand beyond probiotics into a broader health partnership.TalkMarketsPendulum Therapeutics Appoints Amy Errett to Board to Drive Microbiome GrowthPendulum Therapeutics appointed Amy Errett, Founder and CEO of Madison Reed, to its Board of Directors to support the company's expansion in the microbiome healthcare market. Errett brings over two decades of experience building consumer brands, including scaling Madison Reed from startup to a leading direct-to-consumer beauty brand. The appointment is intended to help Pendulum leverage its scientific leadership in microbiome research to reach broader consumer audiences.AijournPendulum Therapeutics Appoints Madison Reed Founder and CEO Amy Errett to Board of DirectorsPendulum Therapeutics announced the appointment of Amy Errett, Founder and CEO of Madison Reed, to its Board of Directors as the company expands its clinically validated microbiome products into mainstream consumer health. Errett, a four-time entrepreneur and former General Partner at venture capital firm Maveron, brings expertise in building consumer brands and scaling mission-driven businesses to guide Pendulum's next phase of growth.PR NewswirePendulum Therapeutics Appoints Madison Reed Founder and CEO Amy Errett to Board of DirectorsPendulum Therapeutics announced the appointment of Amy Errett, Founder and CEO of Madison Reed, to its Board of Directors as part of its expansion into mainstream consumer health with microbiome-based products. Errett brings expertise in building consumer brands and scaling mission-driven businesses, with a track record that includes founding Madison Reed and serving as a General Partner at venture capital firm Maveron. The appointment is intended to guide Pendulum's next phase of growth as consumer awareness of the microbiome's role in health continues to increase.ForbesThe Protein Industrial Complex Is Here. Fiber Wants In.Protein has evolved from a nutritional necessity into a commercial obsession driven by new dietary guidelines, gym culture, and the rise of GLP-1 medications intensifying muscle-loss concerns, with companies like David ($75M Series A), Magic Spoon ($120M total funding), and Slate Milk ($23M Series B) capitalizing on a 12% price premium for protein-labeled products. Pendulum Therapeutics, a gut health startup co-founded by a PhD biochemist and affiliated with Halle Berry as Chief Communications Officer, has engineered Akkermansia muciniphila—reportedly the most important gut strain most consumers have never heard of—using proprietary oxygen-free fermentation processes after raising over $150 million from investors including Mayo Clinic; the company is now launching Gut Fuel, a prebiotic fiber supplement, signaling fiber's rebranding as a foundational component of metabolic and microbiome health. PepsiCo's $1.95 billion acquisition of prebiotic soda brand Poppi has validated the category, with competitors like Olipop (60% market share, $50M Series C) and Supergut ($22M Series B) also gaining traction, as only 5% of Americans meet daily fiber recommendations and brands reposition fiber from a senior digestive aid to a cornerstone of the wellness nutrition stack alongside protein.